Abstract
In the present study, Mouth dissolving tablets of Meloxicam were designed with a view to enhance patient compliance. Meloxicam, a new non-steroidal anti-inflammatory agent mainly used for the treatment of osteoarthritis and rheumatoid arthritis. However, it may cause gastro-intestinal tract disturbances/induce ulcer to avoid these complications we designed Mouth dissolving tablets of Meloxicam. The prepared batches of Mouth dissolving tablets were evaluated for hardness and friability, drug dispersion time, drug content uniformity, wetting time, water absorption ratio and in vitro dispersion time. Based on in vitro dispersion time (approximately 8–30 s), all formulations were tested for in vitro drug release pattern (in Phosphate buffer), Short-term stability (40°C/75% RH for 3 months) and drug-excipient interaction study (IR spectroscopy). Among all the formulations, the formulation prepared by 6% sodium starch glycolate was found to have minimum dispersion time (8.77 s) and Short-term stability studies on the promising formulation indicated that there were no significant changes in drug content and in vitro dispersion time.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Research Journal of Pharmaceutical Dosage Forms and Technology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
